secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2024-04-26T23:59:59+00:00
Accession:  0001213900-24-036645
Event type: debt
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix enters forbearance on $10M note; pauses ENTADFI commercialization
---------------------------------------------------------------------------

- Forbearance with Veru extends April 2024 note maturity to March 31, 2025; interest at 10% on unpaid balance.
- Onconetix to pay Veru 15% of monthly cash receipts from Proteomedix licensing, Proclarix sales, and Labcorp milestones.
- Also to pay 10% of net proceeds from any financing or asset sale through March 2025.
- Altos debenture amended to extend maturity to October 31, 2024.
- Company pauses ENTADFI commercialization, terminates three employees, considers strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/0001213900-24-036645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/ea0204751-8k_oncone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-036645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer